Literature DB >> 15010104

Urine drug testing in pain medicine.

Howard A Heit1, Douglas L Gourlay.   

Abstract

The use of urine drug testing (UDT) has increased over recent years. UDT results have traditionally been used in legal proceedings under supervision of a medical review officer (MRO). In this context, testing has been required by statute or regulation and so is typically not in the "donor's" interest. Physicians, however, can use UDT to assist in monitoring their patient's treatment plan. By using UDT in a patient-centered fashion, both patient and physician interests are maintained. The MRO-based model of testing in the clinical setting can lead to mistrust and a deterioration of the doctor-patient relationship. Clinical testing can enhance the doctor-patient relationship when the results are used to improve communication. A patient-centered model of UDT should be used to improve quality of care. This article discusses why urine is the biological specimen of choice for drug testing; who, when and why to test; testing methods; and, most importantly, interpretation of results.

Entities:  

Mesh:

Year:  2004        PMID: 15010104     DOI: 10.1016/j.jpainsymman.2003.07.008

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  27 in total

Review 1.  Implications of opioid analgesia for medically complicated patients.

Authors:  Howard Smith; Patricia Bruckenthal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  [Risk factors for substance abuse and dependence in opioid therapy for chronic noncancer-related pain].

Authors:  J Jage; A Willweber-Strumpf; C Maier
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

3.  Trends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010.

Authors:  Shahram Shahangian; Todd D Alspach; J Rex Astles; Ajay Yesupriya; William K Dettwyler
Journal:  Arch Pathol Lab Med       Date:  2013-06-05       Impact factor: 5.534

4.  Safe opioid prescribing: a long way to go.

Authors:  Jane M Liebschutz; Daniel P Alford
Journal:  J Gen Intern Med       Date:  2011-09       Impact factor: 5.128

5.  Buyer Beware: Pitfalls in Toxicology Laboratory Testing.

Authors:  D Adam Algren; Michael R Christian
Journal:  Mo Med       Date:  2015 May-Jun

6.  They don't know what they don't know: internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain.

Authors:  Joanna L Starrels; Aaron D Fox; Hillary V Kunins; Chinazo O Cunningham
Journal:  J Gen Intern Med       Date:  2012-07-20       Impact factor: 5.128

7.  Interviewing and Urine Drug Toxicology Screening in a Pediatric Pain Management Center: An Analysis of Analgesic Nonadherence and Aberrant Behaviors in Adolescents and Young Adults.

Authors:  John M Saroyan; Elizabeth A Evans; Andrew Segoshi; Suzanne K Vosburg; Debra Miller-Saultz; Maria A Sullivan
Journal:  Clin J Pain       Date:  2016-01       Impact factor: 3.442

8.  Low use of opioid risk reduction strategies in primary care even for high risk patients with chronic pain.

Authors:  Joanna L Starrels; William C Becker; Mark G Weiner; Xuan Li; Moonseong Heo; Barbara J Turner
Journal:  J Gen Intern Med       Date:  2011-02-24       Impact factor: 5.128

9.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

10.  QT prolongation with methadone.

Authors:  Radhika Dhamija; Susan Bannon
Journal:  Indian J Crit Care Med       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.